Therapeutic agent for skin diseases

Abstract

To provide a therapeutic agent for skin diseases having sufficient acne-treating effects without side effects.SOLUTION: The therapeutic agent for skin diseases contains micro / nano bubbles.SELECTED DRAWING: None

Description

[Technical Field]

[0001] The present invention relates to a skin disease therapeutic agent, and more particularly to a skin disease therapeutic agent that is effective in treating acne.

[0002] So-called "acne" is a type of skin disease called acne vulgaris, and is clinically defined as chronic inflammatory changes occurring in the pores, mainly in the pilosebaceous system. Acne is characterized by areas of skin with seborrheic dermatitis (scaling redness of the skin), comedones (blackheads and whiteheads), papules (pin-sized bumps), pustules (pimples), nodules (large papules), and sometimes scars. These areas include the face, upper chest, and back. While severe acne is inflammatory, acne can also appear in a non-inflammatory form.

[0003] Acne most commonly occurs during adolescence, affecting over 90% of middle and high school students, and often continues into adulthood. During adolescence, acne is usually caused by an increase in male hormones, and both men and women are affected during puberty.

[0004] Acne scars are the result of inflammation within the dermis caused by acne. They are created when excess collagen is produced in one area as the wound attempts to heal itself. Physical acne scars are often referred to as "ice pick scars" because they tend to indent the surface of the skin.

[0005] Pigmented acne scars are usually caused by nodular or cystic acne (painful bumps beneath the skin). These scars often leave inflamed, red marks. In many cases, pigmented acne scars can be prevented by simply avoiding the worsening of the nodules or cysts. If patients attempt to "pop" the nodules or cysts, the pigmented acne scars can become significantly worse and may even bruise the area. Pigmented acne scars almost always fade over time, but they can take anywhere from three months to two years to fade.

[0006] There are still many unknowns about the pathogenesis of acne, but it is generally believed to be a skin disease in which excessive sebum secretion, hair follicle keratinization, and bacteria within hair follicles play important roles, with various factors intertwined in a complex manner. Generally, acne develops through the following process:

[0007] Hyperkeratinization and the formation of keratin plugs and sebaceous plugs (microcomedones) are the earliest changes. Increased production of androgens (DHEA-S) during adrenocortical manifestations leads to enlargement of sebaceous glands and increased sebum production. Microcomedones may enlarge to form open comedones (blackheads) or closed comedones (milia). Comedones are the direct result of plugging of sebaceous glands with sebum, naturally occurring oils, and dead skin cells. In these conditions, the naturally occurring and commensal Propionibacterium acnes causes inflammation, leading to the formation of inflammatory lesions (papules, infected pustules, or nodules) in the microcomedones or the dermis surrounding the comedones, resulting in redness and potentially scarring or hyperpigmentation.

[0008] -Hormonal causes- Hormonal activity, such as the menstrual cycle and puberty, can contribute to the formation of acne. During puberty, increased levels of male hormones called androgens cause the antral glands to enlarge and increase sebum production. The use of anabolic steroids can have a similar effect. Several hormones, including the androgens testosterone, dihydrotestosterone (DHT), and dehydroepiandrosterone sulfate (DHEAS), as well as insulin-like growth factor 1 (IGF-1), have been associated with acne.

[0009] Although the onset of acne vulgaris after puberty is uncommon, this age group is affected by rosacea, which may have a similar appearance. True acne vulgaris in adult women may be a clinical manifestation of underlying conditions such as pregnancy and disorders (polyovarian syndrome or rare Cushing's syndrome). Menopause-associated acne occurs because the production of the natural anti-acne ovarian hormone estradiol ceases at menopause. Estradiol deficiency can lead to thinning hair, flushing, thinning of the skin, wrinkles, vaginal dryness, increased susceptibility to osteopenia and osteoporosis, and also to the induction of acne.

[0010] -Genetic causes- The tendency to develop acne runs in families. For example, school-age boys with acne often have other family members who also have acne. A family history of acne is associated with earlier onset of acne and an increased number of retention acne lesions.

[0011] -Psychological causes- The relationship between acne and stress has been debated, and scientific research has shown that "increased acne severity" is "significantly associated with increased stress levels." The National Institutes of Health lists stress as a factor that may contribute to increased acne flares.

[0012] -Infectious causes- Propionibacterium acnes (P. acnes) is an anaerobic bacterium that may be involved in acne formation.

[0013] -Dietary causes- High glycemic load diets and milk have been linked to worsening acne.

[0014] -Previous knowledge- There are various treatments for acne, including benzoyl peroxide, antibiotics, retinoids, antiseborrheic agents, and nicotinamide. In addition to these treatments, keratolytic soaps, such as those containing salicylic acid and sulfur, are used as adjuvants in acne treatment, helping to reduce skin oiliness. These treatments are thought to work in at least four ways: by normalizing skin exfoliation and preventing pore clogging, by killing Propionibacterium acnes, by anti-inflammatory effects, and by hormonal treatment. However, these treatments can take a long time to treat acne.

[0015] For example, Patent Document 1 discloses a disinfectant containing gold ions as an active ingredient that is used to kill acne bacteria. However, even if the disinfectant disclosed in Patent Document 1 can kill acne bacteria, it cannot effectively treat acne.

[0016] Patent Document 2 also discloses "a composition comprising one or more probiotic bacterial strains and, optionally, a thickened topical formulation of a probiotic compound, a protectant, a moisturizer, an emollient, an abrasive, a salt, and / or a surfactant, wherein the one or more probiotic bacterial strains comprise one or more bacterial strains selected from the group consisting of S. capitis, S. epidermidis, and any combination thereof, the composition formulated for the topical treatment of skin, scalp, or mucosal abnormality disorders, and the composition inhibits the growth of Propionibacterium acnes, a method for treating acne by applying an effective amount of the composition to the skin or mucosa of a subject in need thereof." However, even with the treatment method disclosed in Patent Document 2, even if Propionibacterium acnes can be killed, it cannot effectively treat acne.

[0017] Furthermore, Patent Document 3 discloses a "skin disease treatment device including: a handpiece having a storage space for storing the skin tissue to be treated; a suction module for providing suction pressure to the storage space; a therapeutic light lamp provided in the handpiece for irradiating the skin tissue with intense pulsed light (IPI); and a germicidal light lamp provided in the handpiece for irradiating the skin tissue with germicidal light." Patent Document 3 also describes an example in which ultraviolet light is used as the germicidal light. However, when ultraviolet light is irradiated onto the skin, it can cause ultraviolet allergies, which "cause an overreaction of the immune system, resulting in symptoms such as itching, eczema, and redness of the skin." [Prior art documents] [Patent documents]

[0018] [Patent Document 1] Patent No. 5646277 specification [Patent Document 2] Special Publication No. 2022-501330 [Patent Document 3] Special Publication No. 2016-537118 Summary of the Invention [Problem to be solved by the invention]

[0019] As described above, acne is a skin disease caused by a complex interplay of various factors, but no effective acne treatment has yet been provided. The present invention has been made in consideration of the problems of the prior art, and its object is to provide a skin disease treatment agent that has no side effects and is sufficiently effective in treating acne. [Means for solving the problem]

[0020] The first invention of the present application, which aims to solve the above-mentioned problems, is (1) a skin disease treatment agent containing micro-nano bubbles that can effectively treat acne.

[0021] The second invention of the present application is (2) a skin disease treatment agent according to (1), which includes a drug, a quasi-drug, a medicated cosmetic, or a cosmetic.

[0022] The third invention of the present application is a skin disease treatment agent according to (2), wherein the pharmaceutical, quasi-drug, medicated cosmetic, or cosmetic is a drug having anti-inflammatory, antioxidant, and blood circulation promoting / blood flow improving effects.

[0023] The fourth invention of the present application is (4) the skin disease treatment agent according to (1), (2), or (3), wherein the micro-nano bubbles are produced from one or more gases selected from the group consisting of hydrogen, oxygen, carbon dioxide, and air.

[0024] A fifth invention of the present application is (5) the skin disease treatment agent according to (4), which comprises one or more liquids selected from water and ethanol.

[0025] The sixth invention of the present application is the skin disease treatment agent according to (5), which further comprises (6) a hydrophilic thickener. [Effects of the Invention]

[0026] The present invention cleverly utilizes the effects of micro- and nano-bubbles. Microbubbles are bubbles with diameters between 0.1 mm and 0.001 mm, while nanobubbles are bubbles with diameters between 0.001 mm and 0.000001 mm (1 nm). Micro- and nano-bubbles encompass both. Microbubbles possess three properties—rising, contracting, and collapsing—and exhibit behaviors different from typical bubbles. Microbubbles have high internal pressure, remain in water for long periods, and slowly rise and contract. Because they are negatively charged, they adsorb dirt during the rising and contracting process, and then continue rising and contracting until they finally collapse and become nano-sized. As described above, the first through fifth inventions of the present application utilize the properties of microbubbles, which are much smaller than typical bubbles. This allows micro- and nano-bubbles to easily penetrate the skin, promoting blood circulation and improving blood flow, effectively treating acne without side effects. Furthermore, micro-nano bubble water can be prepared by using one or more liquids selected from water containing micro-nano bubbles and ethanol. Adding a hydrophilic thickener to this micro-nano bubble water can impart viscosity and gelatinize it, making it less likely to drip and easier to apply than water-like skin disease treatments. Furthermore, because hydrophilic thickeners have the ability to hold water, applying a skin disease treatment to the skin containing a hydrophilic thickener can be expected to enhance moisturizing effects and prevent moisture loss. Thus, the sixth invention of the present application, which is achieved by adding a hydrophilic thickener to micro-nano bubble water, can be expected to improve ease of use and moisturizing effects. Examples of hydrophilic thickeners include PEG-240, PEG-400, PEG-14M, polyvinylpyrrolidone, sodium acrylate, alginic acid, sodium alginate, carrageenan, xanthan gum, and guar gum. [Brief explanation of the drawings]

[0027] [Figure 1] Figure 1 is a front view of the micro / nano bubble generating system. [Figure 2] Figure 2 is a perspective view of the micro-nano bubble generating system. [Figure 3] Figure 3 is an enlarged cross-sectional view of the micro-nano bubble generating nozzle. [Figure 4] Figure 4 is an enlarged plan view of the micro-nano bubble generating nozzle. [Figure 5] Figure 5 is an enlarged side view of the micro-nano bubble generating nozzle. [Figure 6] FIG. 6(a) is a cross-sectional view taken along the line BB in FIG. 6(b), and FIG. 6(b) is a plan view of the high-speed liquid jet ejection nozzle. [Figure 7] FIG. 7 is an enlarged cross-sectional view of a high-speed liquid jet spray nozzle. [Figure 8] FIG. 8 is a cross-sectional view of the gas-liquid mixing vessel. [Figure 9] FIG. 9 is an enlarged view of the circled area E in FIG. [Figure 10]FIG. 10 is a cross-sectional view of the gas-liquid mixing vessel including a cross section of the float. [Figure 11] Figure 11(a) is a photograph of the monitor's face before treatment with the skin disease therapeutic agent of the present invention, and Figure 11(b) is a photograph of the monitor's face after 65 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 12] Figure 12(a) is a photograph of the face of another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 12(b) is a photograph of the face of the same monitor after one year of treatment with the skin disease therapeutic agent of the present invention. [Figure 13] Figure 13(a) is a photograph of the face of yet another monitor before treatment with the skin disease treatment agent of the present invention, and Figure 13(b) is a photograph of the face of the same monitor after 71 days of treatment with the skin disease treatment agent of the present invention. [Figure 14] Figure 14(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 14(b) is a photograph of the face of the same monitor after 84 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 15] Figure 15(a) is a photograph of the face of yet another monitor before treatment with the skin disease treatment agent of the present invention, and Figure 15(b) is a photograph of the face of the same monitor after one year of treatment with the skin disease treatment agent of the present invention. [Figure 16] Figure 16(a) is a photograph of the face of yet another monitor before treatment with the skin disease treatment agent of the present invention, and Figure 16(b) is a photograph of the face of the same monitor after 76 days of treatment with the skin disease treatment agent of the present invention. [Figure 17] Figure 17(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 17(b) is a photograph of the face of the same monitor after 115 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 18] Figure 18(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 18(b) is a photograph of the face of the same monitor after 125 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 19]Figure 19(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 19(b) is a photograph of the face of the same monitor after 142 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 20] Figure 20(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 20(b) is a photograph of the face of the same monitor after 84 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 21] Figure 21(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 21(b) is a photograph of the face of the same monitor after 82 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 22] Figure 22(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 22(b) is a photograph of the face of the same monitor after 180 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 23] Figure 23(a) is a photograph of the face of yet another monitor before treatment with the skin disease therapeutic agent of the present invention, and Figure 23(b) is a photograph of the face of the same monitor after 135 days of treatment with the skin disease therapeutic agent of the present invention. [Figure 24] FIG. 24 is a diagram showing the particle size distribution of micro- and nano-bubbles in the skin disease treatment agent of the present invention used in the examples. DETAILED DESCRIPTION OF THE INVENTION

[0028] Micro- and nano-bubbles have various characteristics, such as (a) small bubble diameter, (b) slow rising speed, (c) reduced frictional resistance, (d) high intra-bubble pressure, (e) large gas-liquid interface, (f) large amount of dissolved gas, (g) dissolution and contraction, (h) negatively charged bubble surfaces, (i) as the particle diameter becomes smaller, buoyancy becomes much smaller compared to viscous forces, so that they can remain as ultrafine bubbles in liquid for a long time without floating to the top, and (j) the spherical diameter of the bubbles becomes so small that liquids containing nano-bubbles are invisible to the naked eye and are colorless and transparent. Utilizing these characteristics, micro- and nano-bubbles are expected to be applied in a wide range of fields, such as food, cosmetics, pharmaceuticals, semiconductor cleaning, and plant cultivation.

[0029] The skin disease treatment agent of the present invention contains micro-nano bubbles with the above-mentioned characteristics. Micro-nano bubble water can be prepared using water or ethanol as a medium for liquefying the skin disease treatment agent containing micro-nano bubbles. However, the medium is not limited to water and ethanol, and any medium known to those skilled in the art can be used. Water can be tap water, purified water, natural water, carbonated water, deionized water, alkaline ionized water, deep sea water, distilled water, RO water, purified water, or any other suitable water. Purified water is a solvent used in medical treatment, has superior skin penetration compared to regular water, and is free of impurities, making it suitable for use by people with sensitive skin without worrying about skin irritation. Therefore, purified water is a preferred choice.

[0030] The skin disease treatment agent containing micro-nano bubbles of the present invention is characterized by the fact that the micro-nano bubbles are dispersed in a liquid. Micro-nano bubbles include both microbubbles with diameters of 0.1 mm to 0.001 mm and nanobubbles with diameters of 0.001 mm to 0.000001 mm (1 nm), but the diameter of the micro-nano bubbles preferably ranges from 1 nm to 55 nm. Hydrogen, oxygen, carbon dioxide, and air can be used as gases for the micro-nano bubbles.

[0031] An example of a pharmaceutical, quasi-drug, medicated cosmetic, or cosmetic that can be included in the skin disease treatment agent of the present invention is Nizoral Lotion 2% (trade name), which contains ketoconazole as an active ingredient. Ketoconazole is an imidazole synthetic antifungal drug used medically to treat mycoses, and is used to treat tinea, candidiasis, tinea versicolor, and seborrheic eczema. Ketoconazole has the IUPAC name "1-[4-(4-{[(2R,4S)-2-(2,4-Dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]ethan-1-one."

[0032] Miconazole, an imidazole antifungal agent, can also be used, as it inhibits the biosynthesis of ergosterol, a compound found in fungal cell membranes, just like other imidazole antifungals. Miconazole is primarily applied to the skin and mucous membranes in the form of its nitrate, but it can also be taken orally. It is sometimes incorporated into shampoos, rinses, and liquid soaps to prevent fungal dandruff and eczema. Miconazole has the IUPAC name "(RS)-1-(2-(2,4-Dichlorophenyl)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazol."

[0033] Other than those mentioned above, the drugs, quasi-drugs, medicated cosmetics, and cosmetics that can be contained in the skin disease treatment agent of the present invention include those described in the following paragraphs 0034 to 0057.

[0034] -Improves clogged pores- Acne occurs when pores become clogged with sebum and other substances, causing the proliferation of acne bacteria and inflammation. Therefore, clearing clogged pores is crucial to treating acne. Therefore, when acne is present, it is common to use topical ointments to clear clogged pores. For example, Adapalene Gel / Differin Gel (trade name) can be used. Adapalene Gel / Differin Gel is a topical ointment containing adapalene as its active ingredient. Adapalene inhibits the differentiation of keratinocytes in the epidermis, thinning the stratum corneum and preventing pore narrowing. In other words, by keeping pore openings wide, it prevents and improves clogged sebum and prevents the progression of acne to severe inflammation. Adapalene Gel / Differin Gel prevents clogged pores and suppresses the formation of comedones. Using it at the whitehead stage can prevent the progression to red or yellow acne.

[0035] Additionally, Bepiogel (trade name), which contains benzoyl peroxide as an active ingredient, can be used as a topical ointment to unclog pores. Bepiogel has a peeling effect that exfoliates dead skin cells. This is expected to improve the thickening of the keratin at the entrance to pores. Bepiogel also has antibacterial properties against acne bacteria and staphylococcus, so it can easily peel off dead skin cells and improve clogged pores, while also suppressing the activity of acne-causing bacteria. According to Bepiogel, it can improve inflammatory red acne and make pores less likely to become clogged, which can also be expected to have an acne prevention effect.

[0036] Furthermore, Epiduo Gel (trade name), which contains the active ingredients adapalene and benzoyl peroxide, can be used as a topical ointment to improve clogged pores. Epiduo Gel is a topical ointment that combines adapalene, which thins the keratin, with benzoyl peroxide, which has peeling and anti-pimple properties. According to Epiduo Gel, it can be expected to improve symptoms ranging from whiteheads to highly inflamed red acne.

[0037] Duac Combination Gel (trade name), which contains clindamycin phosphate hydrate and benzoyl peroxide as active ingredients, can also be used. Clindamycin phosphate hydrate is expected to have antibacterial properties against acne bacteria and anti-inflammatory properties by suppressing the accumulation of white blood cells that cause inflammation in the affected area. Furthermore, benzoyl peroxide peels off excess stratum corneum and improves clogged pores, thereby suppressing the formation of comedones. Thus, Duac Combination Gel can improve red and yellow acne.

[0038] -Antibiotics- When acne bacteria and other bacteria grow in clogged pores, inflammation occurs, resulting in red pimples that are painful to the touch or suppurating yellow pimples. Therefore, to quickly treat the inflammation occurring in the pores, it is necessary to use a topical ointment containing an antibiotic with bactericidal and antibacterial properties. One such antibiotic that can be used is Dalacin T Gel (trade name), whose active ingredient is clindamycin. Dalacin T Gel prevents protein synthesis by acne bacteria and staphylococcus bacteria, which worsen acne, and suppresses the inflammation of red pimples.

[0039] Additionally, Aquachim Cream (trade name), a new quinolone antibiotic containing nadifloxacin as its active ingredient, can be used. Aquachim Cream suppresses the bacteria Propionibacterium acnes and Staphylococcus aureus that worsen acne, improving redness and swelling and reducing red acne.

[0040] Additionally, Zeviax (trade name), which contains the antibiotic ozenoxacin as its active ingredient, can be used. Zeviax inhibits the bacteria Propionibacterium acnes and Staphylococcus aureus that worsen acne, improving redness and swelling and reducing red acne.

[0041] In the case of inflamed red acne, oral antibiotics may be used in addition to topical ointments. Typical medications include the following:

[0042] Vibramycin (trade name), which contains doxycycline hydrochloride hydrate as its active ingredient, can be used. Vibramycin kills bacteria by inhibiting bacterial protein synthesis. Vibramycin is particularly effective in treating inflamed red acne.

[0043] Minocycline hydrochloride (brand name) can be used. Minocycline is a drug that kills bacteria by inhibiting bacterial protein synthesis. It is expected to have anti-inflammatory effects and suppress active oxygen, suppressing the accumulation of white blood cells that cause inflammation in the affected area, making it effective in treating inflamed red acne.

[0044] Rulid (brand name), which contains roxithromycin as its active ingredient, can be used. Rulid also kills bacteria by inhibiting bacterial protein synthesis. Rulid is effective in treating red, inflamed acne.

[0045] Farom (brand name), which contains the active ingredient faropenem sodium, can be used. Farom kills bacteria by inhibiting bacterial cell wall synthesis. Farom is effective in treating inflamed red acne.

[0046] -Oral medication- Alternatively, an oral medication called isotretinoin (trade name), which contains a vitamin A derivative, can be used. Isotretinoin is expected to have the effects of suppressing sebum secretion, improving clogged pores, suppressing inflammation, and having antibacterial effects against the acne bacteria that cause acne. Furthermore, isotretinoin not only eliminates acne, but is also expected to prevent its recurrence for a long period of time even after the medication has stopped.

[0047] -Moisturizer- Moisturizing is also important for improving acne. Dry skin can lead to excess sebum secretion to compensate for the dryness, which can lead to a weakening of the skin's barrier function and disruption of cell turnover. For this reason, moisturizers can be used in conjunction with medications to improve clogged skin or antibiotics. A typical moisturizer is Hirudoid (trade name), which contains a heparinoid as its active ingredient. Hirudoid not only moisturizes, but also promotes blood circulation and has anti-inflammatory properties. Furthermore, continued use of Hirudoid helps maintain the skin's barrier function, which can be expected to improve acne.

[0048] -Chinese herbal medicine- Kampo medicine can be used to improve one's constitution so that acne is less likely to occur. Kampo medicine is a good option when regular acne medications don't work, when medications don't suit one's constitution, or when one does not want to take antibiotics for a long period of time. Kampo medicines can be used depending on the condition and location of the acne. Kampo medicines that can be used to treat inflamed red acne are Jumihaidokuto (Jumihaidokuto), Keigairengyoto (Keigairengyoto), and Seijobofuto (Seijobofuto), which are listed below.

[0049] Jūmi-haidoku-to is a traditional Chinese medicine used to treat eczema with pus and moisture, and is sometimes used to treat dermatitis, hives, and other conditions in addition to acne. It is expected to be effective in improving swelling, redness, itchiness, and suppuration of the skin, and the licorice root and thornwort contained in Jūmi-haidoku-to are also expected to have antibacterial properties. Jūmi-haidoku-to can be used as a treatment for red acne that is inflamed.

[0050] Gekkeirenkyoto is a traditional Chinese medicine that is primarily used for nasal symptoms, but it has also been shown to have anti-allergic effects and suppress the production of active oxygen, and can be used as a treatment for inflamed red acne.

[0051] Qingshangfengtang is a Chinese herbal medicine used to treat acne, as well as eczema and dermatitis on the face and head. Qingshangfengtang can be used to treat both whiteheads and inflamed red acne.

[0052] Acne is thought to be related to poor circulation, so Chinese herbal medicines that improve blood flow can be used. Furthermore, if acne persists, Chinese herbal medicines such as Ninjinto, Rikkunshito, and Hochuekito can be used to improve internal organs.

[0053] -Vitamins- The effectiveness of vitamin supplements on acne is unclear, but they can be used as an adjunct to improving physical constitution and treating acne.

[0054] You can use Cinal (brand name), which contains ascorbic acid (vitamin C) and pantothenic acid (vitamin B5) as its active ingredients. Cinal promotes collagen production, inhibits active oxygen that causes skin damage, suppresses melanin production, and is expected to prevent and improve pigmentation caused by acne scars.

[0055] You can use Hythiol (brand name), which contains the amino acid L-cysteine ​​as its active ingredient. Like vitamin C, it acts as an antioxidant and is said to prevent oxidative stress, suppressing the production of melanin pigment and helping to prevent pigmentation.

[0056] You can use Neurovitan (brand name), whose active ingredients are octotiamine (a vitamin B1 derivative), riboflavin (vitamin B2), pyridoxine hydrochloride (vitamin B6), and cyanocovalacin (vitamin B12). These vitamins help keep skin and mucous membranes healthy, and vitamins B2 and B6 play important roles in cell turnover.

[0057] You can use Yubela (trade name), which contains tocopherol acetate (a vitamin E derivative) as its active ingredient. Yubela is expected to improve blood flow, normalize cell turnover, and reduce pigmentation, age spots, and freckles, as well as protect skin cells from oxidative damage.

[0058] Examples of cosmetic ingredients that can be contained in the skin disease treatment agent of the present invention include anti-inflammatory ingredients, antioxidant ingredients, blood circulation promoting / blood flow improving ingredients, antioxidants, preservatives, thickeners, moisturizing ingredients, chelating agents, pH adjusters, plant extracts, fragrances, and pigments.

[0059] Next, we will explain the method for generating the micro-nano bubbles contained in the skin disease treatment agent of the present invention. Figure 1 is a front view of a system for generating micro-nano bubbles, and Figure 2 is a perspective view of the system. In Figures 1 and 2, 1 is a bellows cylinder pump, 2 is a pump controller, 3 is a gas-liquid mixing tank, 4 is a pressure sensor, 5 is a micro-nano bubble generating nozzle attachment, 6 is a liquid suction tube, 7 is a gas suction port, and 8 is a gas suction adjustment valve.

[0060] The bellows cylinder pump 1, whose liquid-contacting parts are made of fluororesin, uses a liquid suction tube 6 and a gas suction adjustment valve 8 to adjust the amount of gas. The liquid and gas mixture is sucked into the pump, agitated inside the bellows, and compressed, dissolving the gas in the liquid. In the present invention, the bellows cylinder pump 1 is sufficient as long as it is metal-free. It may also be made of at least one plastic other than fluororesin, such as general-purpose plastics like polyethylene, polypropylene, and polyethylene terephthalate; engineering plastics like polyacetal, polyamide, polycarbonate, and modified polyphenylene ether; and super-engineering plastics like polyethersulfone, polyphenylene sulfide, polyetheretherketone, and liquid crystal polymer. In this case, using fluororesin and other plastics not only for the pump but also for the liquid-contacting parts can result in a highly reliable and clean micro-nano bubble generator. Furthermore, in the present invention, if strict metal-free cleaning and sterilization are not required, metals and ceramics may be used in addition to the plastics listed above.

[0061] Next, the gas and liquid are agitated by a bellows cylinder pump 1 and pumped into a gas-liquid mixing tank 3. The bellows cylinder pump 1 is usually an air-driven bellows cylinder pump, but an electrically powered one can also be used. The gas and liquid in the gas-liquid mixing tank 3 are subjected to pressure from the bellows cylinder pump 1, which makes it easier for the gas to dissolve. In other words, the pressure at which the gas and liquid are pumped from the bellows cylinder pump 1 is checked by a pressure sensor 4. This method increases the amount of dissolved gas, preparing to increase the amount of micro-nano bubbles generated.

[0062] The liquid that has been pumped into the gas-liquid mixing tank 3 is mixed with the gas, and the gas is dissolved in the liquid before being sent to the micro-nano bubble generating nozzle attachment part 5. The micro-nano bubble generating nozzle attachment part 5 is the part that connects the dissolved gas to a nozzle that produces a large amount of micro-nano bubbles with a diameter of 60 μm or less, preferably 15 μm or less.

[0063] At this time, the pressure sensor 4 monitors the dissolved state of the gas and liquid by observing fluctuations in the liquid pressure between the micro-nano bubble generating nozzle attachment part 5 and the gas-liquid mixing tank 3. This makes it possible to achieve the constant pressure state required for a stable micro-nano bubble generating nozzle.

[0064] This section describes a method for generating micro-nano bubbles using the micro-nano bubble generating system shown in Figures 1 and 2. Gas and liquid are sucked in using the gas suction port 7, liquid suction tube 6, and gas suction adjustment valve 8. Next, the gas-containing liquid is pressurized using a bellows cylinder pump 1. Subsequently, the pressurized gas-containing liquid is mixed with new gas using a pump controller 2 and a gas-liquid mixing tank 3 to enrich the dissolved gas. After that, a high-speed liquid jet injection nozzle (described later) is connected to the micro-nano bubble generating nozzle attachment part 5, and micro-nano bubbles are generated. This process is a dissolved gas atomization process. Micro-nano bubbles can be generated by injecting a gas-dissolved liquid at a pressure equal to or greater than atmospheric pressure through a cylinder with two or more small through-holes from the outside of the cylinder and causing the gas-dissolved liquid to collide with the gas-dissolved liquid at a point inside the cylinder.

[0065] Next, we will explain a method for generating a large amount of micro-nano bubbles from a gas-dissolved liquid. Figure 3 is an enlarged cross-sectional view of a micro-nano bubble generating nozzle, with 11 and 12 representing the outer cases of the nozzle. Outer cases 11 and 12 are arranged opposite each other and fixed with bolts 13 and nuts 14. The gas-dissolved liquid pressurized by a bellows cylinder pump 1 is supplied into the opposing outer cases 11 and 12 as shown by the arrows. 15 and 16 are high-speed liquid jet injection nozzles, and the discharge flow rate and flow velocity of the gas-dissolved liquid can be determined by the size of the nozzle holes.

[0066] Figure 4 is an enlarged plan view of the micro-nano bubble generating nozzle, and liquid containing micro-nano bubbles is ejected in the direction indicated by the arrow.

[0067] A method for generating micro-nano bubbles using the water flow discharged from this high-speed liquid jet injection nozzle is described below. The water is discharged from the bellows cylinder pump 1 at a pressure of 0.2 MPa to 0.6 MPa, and the gas-dissolved liquid discharged from the high-speed liquid jet injection nozzles 15 and 16 collide with each other, generating a large amount of micro-nano bubbles by crushing the gas-dissolved liquid with the water hammer force.

[0068] Figure 6(a) is a cross-sectional view taken along the line BB in Figure 6(b), and Figure 6(b) is a plan view of the high-speed liquid jet jet nozzle. The high-speed liquid jet jet nozzles 15 and 16 are centered using a center pin 17 that determines the center, and are aligned and fixed using positioning pins 18 and 19.

[0069] Figure 7 is an enlarged cross-sectional view of a high-speed liquid jet nozzle, and as shown in Figure 6, the high-speed liquid jet nozzles 15 and 16 are arranged facing each other, and the gas-dissolved liquid discharged from one high-speed liquid jet nozzle 15 or 16 crashes into the gas-dissolved liquid discharged from the other high-speed liquid jet nozzle 15 or 16, causing a water hammer force to break up the gas-dissolved liquid and generate a large amount of micro-nano bubbles. In order to supply the gas-dissolved liquid as a high-speed jet, the gas-dissolved liquid is ejected from the small flow path holes 15a and 16a by being rapidly squeezed by the nozzle portions 15b and 16b, and the collision of the jet streams ejected from the nozzle portions 15b and 16b breaks up the gas-dissolved liquid, generating a large amount of micro-nano bubbles.

[0070] The reason for sending the liquid at high pressure is to increase the speed at which the liquid comes out of the small holes. In other words, by colliding the liquid at high speed, the impact energy increases, making it possible to generate a larger number of smaller micro-nano bubbles.

[0071] Let F be the force that occurs when the gas-dissolved liquid collides. Let the density of the liquid be ρ (g / cm 3 ) and S is the cross-sectional area of ​​the nozzle (cm 2) and the liquid velocity is V (cm / sec), then F = ρSV 2 To optimize F, it is necessary to consider the relationship between the density of the liquid, the cross-sectional area of ​​the nozzle, and the velocity of the liquid.

[0072] It is believed that pumps that generate higher pressures can generate more micro- and nano-bubbles. For example, there are high-pressure pumps with discharge pressures of 0.5 MPa to 250 MPa. When using such pumps, the liquid velocity increases in proportion to the pressure, and the water hammer force F increases as the square of V, so the amount of micro- and nano-bubbles generated is likely to increase. However, applying such high-pressure pumps to micro- and nano-bubble generators makes it difficult to meet various requirements, such as light weight, compact size, metal-free design, and low maintenance costs.

[0073] However, by using the micro-nano bubble generating nozzles shown in Figures 3 to 5 and the high-speed liquid jet injection nozzles shown in Figures 6 and 7 in the micro-nano bubble generating system shown in Figures 1 and 2, it is possible to generate a volume of micro-nano bubbles equivalent to or greater than conventional levels, provided that the pressure at which the gas-dissolved liquid in a gas-liquid mixture is injected is atmospheric pressure (approximately 0.1 MPa) or higher. Furthermore, by setting this pressure at 0.2 MPa or higher, it is possible to generate a sufficient amount of micro-nano bubbles for thorough cleaning and sterilization. Because the lower limit of the injection pressure of the gas-dissolved liquid can be lowered to 0.2 MPa, a pump suitable for eliminating the effects of metal contamination, namely, a compressed air-driven or electric bellows cylinder pump 1 made of fluororesin, as shown in Figures 1 and 2, can be used. Furthermore, when using a compressed air-driven or electric bellows cylinder pump, the volume of micro-nano bubbles tends to saturate when the injection pressure of the dissolved liquid exceeds 0.6 MPa. Therefore, in the present invention, the pressure when spraying the gas-dissolved liquid is preferably 0.2 to 0.6 MPa.

[0074] The micro-nano bubble generating nozzle of the present invention is capable of spraying a jet stream of gas-dissolved liquid at atmospheric pressure or higher, preferably at a pressure of 0.2 to 0.6 MPa, which is lower than conventional pressures. Therefore, the diameter of the nozzle portions indicated by 15b and 16b in Fig. 7 is preferably 0.1 to 6.0 mm. In Fig. 7, the flow path small holes 15a and 16a need only have a throttle function for converting the gas-dissolved liquid into a high-speed jet and can be formed in a continuously tapered shape toward the nozzle portions 15b and 16b. The amount of micro-nano bubbles generated is mainly determined by the diameter of the nozzle portions 15b and 16b; therefore, the flow path small holes 15a and 16a can also be omitted.

[0075] Figure 8 is a cross-sectional view of the gas-liquid mixing vessel 3. Figure 9 shows an enlarged view of the circled area E in Figure 8. Conventional gas-liquid mixing vessels mix gas and liquid at high pressure, but when the gas and liquid are mixed and sent using a pump, they are mixed by spraying them like a fountain from the top inside the gas-liquid mixing vessel. However, this method is inefficient at mixing and does not allow for a large amount of micro-nano bubbles to be generated.

[0076] Therefore, as shown in Figure 8, gas and liquid are sent from a pump in the direction of arrow A to arrow B, and then sent to gas-liquid injection pipes 22 and 23. As shown in Figure 9, in order to increase the efficiency of gas-liquid mixing when the gas and liquid are discharged from hole 22a of gas-liquid injection pipe 22 and hole 23a of gas-liquid injection pipe 23, the water hammer caused by colliding the liquid from the directions of arrows X and Y is utilized, which efficiently mixes the gas and liquid, quickly produces a gas-liquid mixture that serves as the raw material for micro-nano bubbles, and also increases the mixing ratio of the gas and liquid. In Figure 8, 24 is a Teflon (registered trademark) side wall.

[0077] The float 21 shown in Figure 8 is placed with the purpose of safely discharging excess gas to the outside when too much gas is mixed with the gas-liquid mixture, and functions to adjust the amount of gas and liquid to an appropriate level. In other words, by eliminating the problem of excess gas remaining in the gas state flowing into the nozzle and inhibiting the generation of micro-nano bubbles, the amount of micro-nano bubbles generated can be adjusted and stabilized.

[0078] 10 is a cross-sectional view of the gas-liquid mixing vessel including a cross-section of the float. This float 21 has a float tip 21a (sharp), a reinforcing rib 21b that prevents the float 21 from collapsing due to the pressure of the liquid, and a stopper 21c.

[0079] In order to mix gas and liquid, it is important to increase the contact area between the gas and liquid to increase the efficiency with which the gas dissolves in the liquid. If this gas dissolution efficiency decreases, there will be a shortage of gas, which is fatal to the generation of micro-nano bubbles, and this will lead to a shortage of micro-nano bubbles.

[0080] After examining the liquid-to-gas ratio to determine whether it increases the amount of micro-nano bubbles generated, we found that a volume ratio of 60% liquid to 40% gas in the gas-liquid mixing vessel is the ideal balance. To automatically control the ratio, the buoyancy of the liquid in the float 21 is used to discharge excess gas through the excess gas outlet 26 of the float receiver 25. This automatic adjustment of the gas volume optimizes the mixing of the dissolved gas and liquid, stabilizes the amount of micro-nano bubbles generated, and increases the amount of micro-nano bubbles generated. To increase the amount of micro-nano bubbles generated, it is preferable to control the volume ratio of liquid to gas in the gas-liquid mixing vessel within a range of 50:50 to 95:5, with a higher liquid ratio. The float 21 can be installed not only inside the gas-liquid mixing vessel 3 but also outside it. In this case, the volume ratio of liquid to gas present inside the gas-liquid mixing vessel 3 can be controlled by connecting the inside and outside of the vessel 3 with a connecting pipe or other means. [Example]

[0081] Below, we will explain an example of the present invention, which uses a skin disease treatment agent that combines purified water containing micro- and nano-bubbles produced from oxygen and having the particle size distribution shown in Figure 24 with a drug, quasi-drug, medicated cosmetic, or cosmetic, such as Nizoral, but the present invention is not limited to this description. Various changes and modifications are possible without departing from the technical scope of the present invention.

[0082] In order to confirm the effectiveness of the skin disease therapeutic agent of the present invention, the following test was conducted using 13 subjects (2 men and 11 women) aged 16 to 32 as monitors. Photographs of the faces of the 13 monitors before and after treatment with the skin disease therapeutic agent of the present invention are shown in Figures 11 to 23, and the ages of the 13 monitors and the treatment period with the skin disease therapeutic agent of the present invention for each monitor are shown in Table 1 below.

[0083] [Table 1]

[0084] For the 13 subjects shown in Table 1, a liquid containing 10 g of "Nizoral Lotion 2%" containing 2% ketoconazole and 80 cc of purified water containing oxygen micro-nano bubbles generated by the micro-nano bubble generating system described with reference to Figures 1 to 10 was directly applied to the face of each subject using a spray bottle. After the liquid appeared to dry (approximately 30 seconds), each subject applied an appropriate amount of "Dalacin T Gel 1%" containing 1% clindamycin phosphate or "Aquachim Cream 1%" containing 1% nadifloxacin directly to their face with their hands. There are no limitations on the method of application of the skin disease treatment agent of the present invention to the face, and it can be applied in a shower-like form. The pressure and flow rate of the shower-like skin disease treatment agent can be adjusted as needed to avoid facial damage and discomfort to the shower recipient. Unless particularly uncomfortable, stronger pressure and higher flow rates are preferred. The application time of the skin disease therapeutic agent of the present invention to the face per application can be adjusted appropriately taking into account the condition of acne on the face, and can be 10 to 20 seconds, 30 to 60 seconds, 1 to 2 minutes, 3 to 5 minutes, or even longer. The skin disease therapeutic agent of the present invention can be applied to the face once a day, twice a day, three times a day, four times a day, or more. It is preferable to continue application until the desired effect is achieved, and the effect usually appears within several weeks to several months, for example, about 3 to 4 months.

[0085] The micro-nano bubbles in the skin disease treatment agent of the present invention are preferably small in size and abundant in quantity. This is because applying a large amount of small micro-nano bubbles to the face allows them to penetrate deep into pores and remove more waste products. Figure 24 shows the particle size distribution of micro-nano bubbles in a liquid containing 10 g of "Nizoral Lotion 2%" containing 2% ketoconazole and 80 cc of purified water containing oxygen micro-nano bubbles generated by the micro-nano bubble generator described above, which was applied directly to the faces of 13 subjects shown in Table 1. The horizontal axis of Figure 24 represents particle size (nm) and the vertical axis represents particle number (number). These micro-nano bubbles contain very small particles with diameters of approximately 1 to 5 nm, so they were measured using dynamic light scattering. Particles undergo Brownian motion in liquid; Brownian motion is faster for small particles and slower for larger particles. When these particles are irradiated with laser light, the intensity of the scattered light fluctuates due to this Brownian motion. Therefore, a rapidly changing fluctuation signal is obtained from small particles, and a slowly changing fluctuation signal is obtained from large particles. Dynamic light scattering is the method of calculating particle diameter by analyzing this fluctuation signal. When measurements are performed using dynamic light scattering, the scattered light intensity (It) is obtained using a highly sensitive detector such as a photomultiplier tube, and the scattered light intensity is expressed in the form of a correlation function as shown in equation (1) below. Q=<I(t)·I(t+γ)> =C1[1+C2exp(-2Γγ)] (1) Q is the scattering vector, t is the time, γ is the time difference, Γ is the decay constant, and C1 and C2 are constants. Γ is related to the diffusion coefficient D of particles undergoing Brownian motion and is expressed in the form of the following equation (2), and the scattering vector g is expressed in the form of the following equation (3). Γ=D·Q 2 (2) g=(4πn / λ0)sin(θ / 2) (3) λ0 is the wavelength of the laser light, and θ is the scattering angle. The diffusion coefficient D can be calculated from equations (1), (2), and (3). Then, the particle diameter can be calculated from the diffusion coefficient D using the Stokes-Einstein equation, expressed as equation (4) below. D=kT / (3πηx) (4) where k is the Boltzmann constant, T is the absolute temperature, η is the viscosity, and x is the particle diameter.

[0086] FIG. 24 shows the particle size distribution of the micro-nano bubbles contained in the skin disease treatment agent of the present invention, with approximately 85% having a diameter in the range of 1 to 5 nm, approximately 90% having a diameter in the range of 1 to 10 nm, and no bubbles exceeding 55 nm. In the examples of the present invention, micro-nano bubbles corresponding to this particle size distribution and produced from oxygen are referred to as oxygen micro-nano bubbles.

[0087] The temperature of the skin disease therapeutic agent of the present invention may be within a temperature range that does not cause discomfort to the person taking a shower, and can be, for example, 25 to 30°C, 30 to 33°C, 33 to 36°C, 36 to 39°C, or 40 to 42°C.

[0088] Thirteen subjects (see Table 1) received a liquid containing 2% ketoconazole "Nizoral Lotion 2%" and purified water containing oxygen micro- and nanobubbles generated by the micro- and nanobubble generator described above, in a ratio of 10 g of the former to 80 cc of the latter. Each subject was sprayed with a spray of approximately 0.2-0.5 cc per application for approximately 20 seconds, once or twice daily. After the liquid appeared to have dried (approximately 30 seconds), each subject applied an appropriate amount of "Dalacin T Gel 1%" containing 1% clindamycin phosphate or "Aquachim Cream 1%" containing 1% nadifloxacin directly to their face with their hands. Subjects who applied the spray twice were given a 6-10 hour interval between the first and second applications. The subject with the shortest treatment period showed results after only 65 days (a 16-year-old female in Table 1, see Figure 11). The oxygen micro- and nano-bubbles were generated in a gas-liquid mixing vessel with a volume ratio of 60% liquid to 40% gas.

[0089] (a) in each of Figures 11 to 23 is a photograph of the monitor's face before treatment with the skin disease therapeutic agent of the present invention, and (b) in each of Figures 11 to 23 is a photograph of the monitor's face after treatment with the skin disease therapeutic agent of the present invention for a predetermined number of days. A comparison of the face before treatment (photograph on the left) and the face after treatment (photograph on the right) in each figure is as follows.

[0090] Figure 11 shows that the acne in the center of the forehead has disappeared after treatment. It is difficult to tell because Figure 11 is shown in black and white, but the acne in the center of the forehead before treatment was red.

[0091] Figure 12 shows that the acne that was visible almost all over the face before treatment has almost completely disappeared after treatment. It is difficult to tell because Figure 12 is shown in black and white, but the acne that was visible almost all over the face before treatment is red acne.

[0092] Figure 13 shows that the color of the shadowy area that was visible on the left cheek before treatment has lightened overall after treatment. Although it is difficult to see because Figure 13 is shown in black and white, there was a slight red area on the left cheek before treatment, but it was confirmed that the red color had lightened after treatment.

[0093] Figure 14 shows that the number of pimples that were seen over almost the entire forehead before treatment has decreased after treatment. Figure 14 is shown in black and white, so it is difficult to tell, but the pimples that were seen over almost the entire forehead before treatment are red pimples.

[0094] Figure 15 shows that there were many pimples on the forehead and right cheek before treatment. After treatment, the number of pimples was significantly reduced, and the size of the pimples was also significantly reduced. Although it is difficult to see in Figure 15 because it is shown in black and white, the pimples seen on the forehead and right cheek before treatment were red pimples.

[0095] Figure 16 shows that the number of pimples that were present on both cheeks and on the chin below the lower lip before treatment has been significantly reduced and the size of the pimples has also been significantly reduced after treatment. Figure 16 is shown in black and white, so it is difficult to see, but the pimples that were present on both cheeks and on the chin below the lower lip before treatment are red pimples.

[0096] Figure 17 shows that the acne that was present on the left cheek and on the chin below the lower lip before treatment has almost completely disappeared after treatment. It is difficult to see because Figure 17 is shown in black and white, but the acne that was present on the left cheek and on the chin below the lower lip before treatment was red acne.

[0097] Figure 18 shows that the acne seen on the left cheek before treatment has almost completely disappeared after treatment. It is difficult to tell because Figure 18 is shown in black and white, but the acne seen on the left cheek before treatment was red acne.

[0098] Looking at Figure 19, we can see that the four pimples that were seen between the left and right eyebrows before treatment have merged into one after treatment. It is difficult to tell because Figure 19 is shown in black and white, but the pimples that were seen between the left and right eyebrows before treatment are blackheads.

[0099] Looking at Figure 20, we can see that the acne that was close to the left nostril before treatment has disappeared after treatment. It is difficult to tell because Figure 20 is shown in black and white, but the acne that was close to the left nostril before treatment was a red acne.

[0100] Looking at Figure 21, we can see that the color of the shadowy areas that were visible on both cheeks before treatment has lightened overall after treatment. Although it is difficult to see because Figure 21 is shown in black and white, there were slight red areas on both cheeks before treatment, but it was confirmed that the red color had lightened after treatment.

[0101] Looking at Figure 22, we can see that the large pimples seen on the right cheek before treatment have almost completely disappeared after treatment, and the numerous pimples seen on the left cheek before treatment have become smaller overall after treatment. Figure 22 is shown in black and white, so it is difficult to tell, but the pimples seen on both cheeks before treatment are red pimples.

[0102] Looking at Figure 23, we can see that the acne that was seen between the left and right eyebrows and on the forehead above the left eyebrow before treatment has become significantly smaller after treatment. We can also see that the color of the shadow-like areas that were seen on the left and right cheeks before treatment has become lighter overall after treatment. Figure 23 is shown in black and white, so it is difficult to tell, but all of the acne seen before treatment is red.

[0103] The observation results of Figures 11 to 23 are summarized below. Although the degree of improvement differed depending on the monitor, it is clear that the skin disease treatment agent of the present invention improves acne symptoms.

[0104] As described above, it has been found that acne symptoms can be improved by using the skin disease treatment agent of the present invention, which is made by blending purified water containing extremely fine oxygen micro-nano bubbles, none of which have a diameter exceeding 55 nm, with a drug, quasi-drug, medicated cosmetic, or cosmetic, such as Nizoral lotion.

[0105] In the skin disease treatment agent of the present invention shown in the above examples, the ratio of Nizoral lotion to purified water containing oxygen micro-nano bubbles was 10 g of a 2% solution of Nizoral lotion to 80 cc of purified water containing oxygen micro-nano bubbles. However, the same effects can be obtained if the ratio of the former to the latter is 5 to 20 g of a 2% solution of Nizoral lotion to 50 to 200 cc of purified water containing oxygen micro-nano bubbles. In addition, in the above test, a liquid containing 10g of a 2% solution of Nizoral lotion and 80cc of purified water containing oxygen micro-nano bubbles was applied to the face of the monitor, and then, after the liquid applied to the face appeared to have dried, "Dalacin T Gel 1%" or "Aquachim Cream 1%" was applied to the face. However, instead of "Dalacin T Gel 1%" or "Aquachim Cream 1%", an appropriate drug, quasi-drug, medicated cosmetic or cosmetic product listed in paragraphs 0034 to 0057 may also be used.

[0106] Instead of the 2% solution of Nizoral lotion, miconazole can be used, or an appropriate product can be used from among the pharmaceuticals, quasi-drugs, medicated cosmetics, or cosmetics described in paragraphs 0034 to 0057. [Industrial Applicability]

[0107] The therapeutic agent for skin diseases of the present invention can be widely applied to the treatment of acne. [Explanation of symbols]

[0108] 1 Bellows Cylinder Pump 2 pump controller 3 Gas-liquid mixing tank 4 Pressure Sensors 5 Micro / nano bubble generating nozzle attachment part 6 Liquid suction tube 7 Gas suction port 8 Gas suction adjustment valve 11 Outer case 12 Outer case 13 volts 14 Nut 15 High-speed jet liquid injection nozzle 15a Small hole for flow path 15b Nozzle part 16 High-speed jet liquid injection nozzle 16a Small hole for flow path 16b Nozzle part 17 Center pin 18 Locating pin 19 Locating pin 21 Float 21a Float tip 21b Reinforcement rib 21c Stopcock 22 Gas-liquid injection pipe 23 Gas-liquid injection pipe 24 Teflon sidewall 25 Float holder 26 Excess gas outlet

Claims

1. A skin disease treatment agent containing micro-nano bubbles that can effectively treat acne.

2. The skin disease treatment agent according to claim 1, which comprises a drug, a quasi-drug, a medicated cosmetic, or a cosmetic.

3. The skin disease treatment agent according to claim 2, wherein the pharmaceutical product, quasi-drug, medicated cosmetic, or cosmetic is a drug having anti-inflammatory, antioxidant, and blood circulation promoting / blood flow improving effects.

4. 4. The skin disease therapeutic agent according to claim 1, 2 or 3, wherein the micro-nano bubbles are produced from one or more gases selected from the group consisting of hydrogen, oxygen, carbon dioxide and air.

5. 5. The skin disease treatment agent according to claim 4, comprising one or more liquids selected from water and ethanol.

6. The skin disease treatment agent according to claim 5, further comprising a hydrophilic thickener.

Images